참고문헌
- Bai Q, Chen F, Qi J, et al (2007). Relationship between HER-2/neu expression and androgen independent prostate cancer. Zhonghua Nan Ke Xue, 13, 414-416
- Craft N, Shostak Y, Carey M, et al (1999). A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med, 5, 280-5. https://doi.org/10.1038/6495
- Guyader C, Ceraline J, Gravier E, et al (2012). Risk of hormone escape in a human prostate cancer model depends on therapy modalities and can be reduced by tyrosine kinase inhibitors. PloS ONE, 7. http://doi.10.1371/journalpone.Oc42252
- Fehm T, Mller V, Aktas B, et al (2010). HER-2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective multicentre trial. Breast Cancer Res Treat, 124, 403-12 https://doi.org/10.1007/s10549-010-1163-x
- Hudis CA (2007). Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med, 357, 39-51. https://doi.org/10.1056/NEJMra043186
- Lara PN, Meyers FJ, Gray CR, et al (2002). Her-2/neu is overexpressed infrequently in patients with prostate carcinoma. Cancer, 94, 2584-9 https://doi.org/10.1002/cncr.10526
- Liu HL, Gandour-Edwards R, Lara PN Jr, et al (2001). Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization. Cancer J, 7, 395-403.
- Montironi R, Mazzucchelli R, Barbisan F, et al.(2006). HER-2 expression and gene amplication in pTa Gleason score 6 prostate cancer incidentally detected in cystoprostatectomy: comparison with clinically detected androgen dependent and androgen independent cancer. Hum Pathol, 37, 1137-44. https://doi.org/10.1016/j.humpath.2006.04.004
- Murray NP, Badinez LV, Duenas R, et al (2011). Positive HER- 2 protein expression in circulating prostate cells and micro-metastasis, resistant to androgen blockage but not diethylstilbestrol. Indian J Urol, 27, 200-207. https://doi.org/10.4103/0970-1591.82838
- Murray NP, Reyes E, Orellana N, et al (2013). Secondary circulating prostate cell in prostate cancer patients after radical prostatectomy and without evidence of disease predict biochemical failure. TWSJ Urol. http://doi.10.1155/2013/281291
- Neto AS, Tobias-Machado M, Wroclawski ML, et al (2010). Her-2/neu expression in prostate adenocarcinoma: a systematic review and meta-analysis. J Urol, 184, 842-50. https://doi.org/10.1016/j.juro.2010.04.077
- Osman I, Scher HI, Drobnjak M, et al (2001). HER-2/ neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res. 7, 2643-7.
- Ratan HL, Gescher A, Steward WP, et al (2003). ErbB receptors: possible therapeutic targets in prostate cancer? BJU Int. 92, 890-5. https://doi.org/10.1111/j.1464-410X.2003.04503.x
- Rink M, Chun FK, Dahlem R, et al (2012). Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. Eur Urol, 61, 810-7. https://doi.org/10.1016/j.eururo.2012.01.017
- Shariat SF, Bensalah K, Karam JA, et al (2007). Preoperative plasma HER-2 and EGFR for staging and prognostication in patients with clinically localized prostate cancer. Clin Cancer Res, 13, 5377-84 https://doi.org/10.1158/1078-0432.CCR-07-0330
- Siampanopoulou M, Galaktidou G, Dimasis N, et al (2013). Profiling serum HER-2/neu in prostate cancer. Hippokratia, 17, 108-112
- Signoretti S, Montironi R, Manola J, et al (2000). Her- 2 neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst, 92, 1918-25. https://doi.org/10.1093/jnci/92.23.1918
- Weiss L (1990). Metastatic inefficiency. Adv Cancer Res, 54, 159-211. https://doi.org/10.1016/S0065-230X(08)60811-8
- Wen Y, Hu MC, Makino K, et al (2000). HER-2/ neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res, 60, 6841-5.
- Yeh S, Lin HK, Kang HY, et al (1999). HER-2/neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Natl Acad Sci USA, 96, 5458-63. https://doi.org/10.1073/pnas.96.10.5458
- Zahir ST, Tafti HF, Rahmani K (2014). Overepression of HER-2/ neu in patients with prostatic adenocarcinoma. Asian Pac J Cancer Prev, 15, 6425-8 https://doi.org/10.7314/APJCP.2014.15.15.6425
피인용 문헌
- The Synergistic Effects Study of C-myc and C-erbB-2 in the Carcinogenesis of Gastric Carcinoma vol.07, pp.12, 2017, https://doi.org/10.4236/ojgas.2017.712032
- Re-expression of microRNA-4319 inhibits growth of prostate cancer via Her-2 suppression vol.20, pp.11, 2018, https://doi.org/10.1007/s12094-018-1871-y
- Systems Oncology: Bridging Pancreatic and Castrate Resistant Prostate Cancer pp.1532-2807, 2018, https://doi.org/10.1007/s12253-018-0467-8
- Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management vol.51, pp.1, 2018, https://doi.org/10.1186/s40659-018-0180-9